Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer M, Zile MR, Kramer CM, et al. (2025). New England Journal of Medicine.
Summary
Tested tirzepatide in 731 people with heart failure with preserved ejection fraction and obesity, a group in which excess weight raises risk. The two primary endpoints were a composite of cardiovascular death or a worsening heart-failure event, and change in a standard heart-failure quality-of-life questionnaire at 52 weeks. Included here because it is the first cardiovascular outcome evidence for the compound rather than a weight or glucose measure.